Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits.
X-ray imaging
floating tablets
in vivo pharmacokinetic studies
losartan potassium
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
10 Oct 2021
10 Oct 2021
Historique:
received:
22
09
2021
revised:
06
10
2021
accepted:
07
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH, it shows poor aqueous solubility, which leads to poor bioavailability and lowers its therapeutic effectiveness. The main aim of this research was to develop a direct compressed effervescent floating matrix tablet (EFMT) of LP using hydroxyl propyl methylcellulose 90SH 15,000 (HPMC-90SH 15,000), karaya gum (KG), and an effervescent agent, such as sodium bicarbonate (SB). Therefore, an EFMT has been developed to prolong the stomach residence time (GRT) of a drug to several hours and improve its bioavailability in the stomach region. The blended powder was evaluated for pre-compression characteristics, followed by post-compression characteristics, in vitro floating, water uptake studies, and in vitro studies. The optimized formulation of EFMT was investigated for in vivo buoyancy by X-ray imaging and pharmacokinetic studies in Albino rabbits. The results revealed that the parameters of pre- and post-compression were within the USP limits. All tablets showed good floating capabilities (short floating lag time <1 min and floated for >24 h), good swelling characteristics, and controlled release for over 24 h. The Fourier-transform infrared (FTIR) and differential scanning calorimetry (DSC) spectra showed drug-polymer compatibility. The optimized formulation F3 (HPMC-90SH 15,000-KG) exhibited non-Fickian diffusion and showed 100% drug release at the end of 24 h. In addition, with the optimized formulation F3, we observed that the EFMT floated continuously in the rabbit's stomach area; thus, the GRT could be extended to more than 12 h. The pharmacokinetic profiling in Albino rabbits revealed that the relative bioavailability of the optimized LP-EFMT was enhanced compared to an oral solution of LP. We conclude that this a potential method for improving the oral bioavailability of LP to treat hypertension effectively.
Identifiants
pubmed: 34685235
pii: polym13203476
doi: 10.3390/polym13203476
pmc: PMC8538939
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Khalid University
ID : RGP-2, 168-42
Références
Drug Des Devel Ther. 2020 Jul 14;14:2741-2757
pubmed: 32764875
Eur J Pharm Biopharm. 2010 Feb;74(2):332-9
pubmed: 19932750
Int J Pharm. 2016 Aug 20;510(1):144-58
pubmed: 27173823
Int J Pharm Investig. 2012 Apr;2(2):83-9
pubmed: 23119237
J Pharm Pharmacol. 2016 Jun;68(6):772-80
pubmed: 27018771
Int J Pharm. 2020 May 15;581:119267
pubmed: 32243969
Eur J Pharm Sci. 2014 Jul 16;58:34-43
pubmed: 24704154
Int J Pharm. 2015;486(1-2):297-305
pubmed: 25843757
Eur J Pharm Biopharm. 2015 Aug;94:513-20
pubmed: 26143367
Pharm Res. 1988 Aug;5(8):533-6
pubmed: 3244664
Int J Pharm. 2019 Dec 15;572:118783
pubmed: 31678393
J Control Release. 2000 Feb 3;63(3):235-59
pubmed: 10601721
Int J Pharm. 2021 Jan 5;592:120113
pubmed: 33246050
J Pharm Sci. 2011 Jan;100(1):150-63
pubmed: 20572054
Pharmaceutics. 2020 Feb 06;12(2):
pubmed: 32041184
AAPS PharmSciTech. 2012 Dec;13(4):1073-83
pubmed: 22907778
Int J Pharm. 2010 Oct 15;398(1-2):1-8
pubmed: 20655998
Eur J Pharm Sci. 2003 Jan;18(1):37-45
pubmed: 12554071
Int J Pharm. 2020 Apr 15;579:119185
pubmed: 32112929
AAPS PharmSciTech. 2019 Jan 2;20(1):35
pubmed: 30604045
Drugs. 2005;65(18):2657-74
pubmed: 16392883